<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462095</url>
  </required_header>
  <id_info>
    <org_study_id>ALL--2016</org_study_id>
    <nct_id>NCT03462095</nct_id>
  </id_info>
  <brief_title>De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Non-intensive But Non-interruptive Treatment of Adult Ph-negative Acute Lymphoblastic Leukemia With Randomization for Maintenance or Autologous Hematopoietic Stem Cell Transplantation (HSCT) Followed by Maintenance in T-cell ALL Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks,
      L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the
      whole treament, T-ALL patients in complete remossion (CR) after the informed consent are
      randomized to: auto-HSCT vs no auto-HSCT, - with the similar further maintenance. Stem cell
      harvest is performed after the 3rd consolidation by G-SCF disregarding minimal residual
      disease (MRD) level. Auto-HSCT is planned after the 5th consolidation phase. All primary bone
      samples are collected and tested for cytogenetics and molecular markers, all included
      patients are monitored by flow cytometry by aberrant immunophenotype in a centralized lab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  7 days prednisolone prephase

        -  8 weeks induction with de-escalation of induction chemotherapy: 3 instead of 4
           dauno/vncr pulses,

             1. instead of 2 Cph injections during induction,

             2. instead of 4 ARA-C blocks, distribution of of L-asp injections through all phases

        -  After CR achievement T-cell ALL patients are being randomized to auto-HSCT vs no
           auto-HSCT

        -  Non-interruptive 5 consolidation phases with dose modification according to WBC and
           platelets count after CR achievement. Rotation of consolidation is permitted

        -  After the 3rd consolidation stem cells harvesting is carried out for T-cell ALL patients
           randomized to auto-HSCT

        -  Auto-HSCT after the 5th consolidation phase with non-myeloablative CEAM conditioning

        -  2 years maintenance for all patients

        -  21 TIT through the whole treatment with higher intensity during induction|consolidation

        -  Centralized MRD monitoring at +70 d, + 133 d, + 190 days; before and after auto-HSCT

        -  Allo-HSCT is planned only for very high risk patients (11q23 ALL, MRD positivity at day
           +190)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5-years</time_frame>
    <description>Impact of autologous HSCT on DFS in T-cell ALL patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRD-negativity after consolidation</measure>
    <time_frame>6 months</time_frame>
    <description>Minimal Residual Disease clearance on non-intensive but non-interruptive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-years</time_frame>
    <description>Impact of de-escalated approach on OS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Precursor Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <arm_group>
    <arm_group_label>no Auto-HSCT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auto-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous HSCT</intervention_name>
    <description>After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance</description>
    <arm_group_label>Auto-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-55 yy, newly diagnosed non-treated Ph-negative ALL

        Exclusion Criteria:

          -  age &gt; 55 yy, Ph-positivity, relapsed|refractory ALL, pretreated ALL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeriy V Savchenko, Academician</last_name>
    <role>Study Director</role>
    <affiliation>National Research Center for hematology, Moscow, Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena N Parovichnikova, MD,PhD</last_name>
    <phone>+79161252623</phone>
    <email>elenap@blood.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga A Gavrilina, M.D.</last_name>
    <email>dr.gavrilina@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Research Center for Hematology</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena N Parovichnikova, MD PhD</last_name>
      <phone>+7(495)6124313</phone>
      <email>elenap@blood.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Each participating site has its on-line access to WEB-data base</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

